Pacific Shuanglin Bio pharmacy Co Ltd (SHE:000403) — Market Cap & Net Worth
Market Cap & Net Worth: Pacific Shuanglin Bio pharmacy Co Ltd (000403)
Pacific Shuanglin Bio pharmacy Co Ltd (SHE:000403) has a market capitalization of $1.37 Billion (CN¥9.39 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #7619 globally and #1681 in its home market, demonstrating a -4.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pacific Shuanglin Bio pharmacy Co Ltd's stock price CN¥9.88 by its total outstanding shares 950397386 (950.40 Million). Also see how large is Pacific Shuanglin Bio pharmacy Co Ltd's balance sheet for a full breakdown of the balance sheet.
Pacific Shuanglin Bio pharmacy Co Ltd Market Cap History: 2015 to 2026
Pacific Shuanglin Bio pharmacy Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.23 Billion to $1.37 Billion (-1.19% CAGR). Also see cash efficiency ratio of Pacific Shuanglin Bio pharmacy Co Ltd for how efficiently the company converts equity into cash flow.
Pacific Shuanglin Bio pharmacy Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pacific Shuanglin Bio pharmacy Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 000403 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.72x
Pacific Shuanglin Bio pharmacy Co Ltd's market cap is 0.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.54x
Pacific Shuanglin Bio pharmacy Co Ltd's market cap is 4.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.50 Billion | $561.21 Million | $50.09 Million | 4.45x | 49.88x |
| 2017 | $2.26 Billion | $685.38 Million | $21.60 Million | 3.30x | 104.82x |
| 2018 | $1.92 Billion | $859.84 Million | $79.98 Million | 2.23x | 23.97x |
| 2019 | $2.46 Billion | $915.66 Million | $160.45 Million | 2.69x | 15.33x |
| 2020 | $5.21 Billion | $1.05 Billion | $185.97 Million | 4.96x | 28.01x |
| 2021 | $3.84 Billion | $1.97 Billion | $391.06 Million | 1.95x | 9.83x |
| 2022 | $3.13 Billion | $2.41 Billion | $587.13 Million | 1.30x | 5.33x |
| 2023 | $3.76 Billion | $2.33 Billion | $612.11 Million | 1.61x | 6.14x |
| 2024 | $2.94 Billion | $2.65 Billion | $745.32 Million | 1.11x | 3.94x |
| 2025 | $1.90 Billion | $2.63 Billion | $419.27 Million | 0.72x | 4.54x |
Competitor Companies of 000403 by Market Capitalization
Companies near Pacific Shuanglin Bio pharmacy Co Ltd in the global market cap rankings as of September 19, 2026. Review Pacific Shuanglin Bio pharmacy Co Ltd (000403) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pacific Shuanglin Bio pharmacy Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Pacific Shuanglin Bio pharmacy Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Pacific Shuanglin Bio pharmacy Co Ltd's market cap moved from $2.23 Billion to $ 1.37 Billion, with a yearly change of -1.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.37 Billion | -27.83% |
| 2025 | CN¥1.90 Billion | -35.21% |
| 2024 | CN¥2.94 Billion | -21.84% |
| 2023 | CN¥3.76 Billion | +20.19% |
| 2022 | CN¥3.13 Billion | -18.59% |
| 2021 | CN¥3.84 Billion | -26.24% |
| 2020 | CN¥5.21 Billion | +111.81% |
| 2019 | CN¥2.46 Billion | +28.28% |
| 2018 | CN¥1.92 Billion | -15.30% |
| 2017 | CN¥2.26 Billion | -9.39% |
| 2016 | CN¥2.50 Billion | +11.83% |
| 2015 | CN¥2.23 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Pacific Shuanglin Bio pharmacy Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.37 Billion USD |
| MoneyControl | $1.37 Billion USD |
| MarketWatch | $1.37 Billion USD |
| marketcap.company | $1.37 Billion USD |
| Reuters | $1.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen… Read more